These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17616501)

  • 1. Osteoporosis risk screening for women in a community pharmacy.
    Liu Y; Nevins JC; Carruthers KM; Doucette WR; McDonough RP; Pan X
    J Am Pharm Assoc (2003); 2007; 47(4):521-6. PubMed ID: 17616501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies.
    Johnson JF; Koenigsfeld C; Hughell L; Parsa RA; Bravard S
    J Am Pharm Assoc (2003); 2008; 48(3):379-87. PubMed ID: 18595823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis screening and education in community pharmacies using a team approach.
    MacLaughlin EJ; MacLaughlin AA; Snella KA; Winston TS; Fike DS; Raehl CR
    Pharmacotherapy; 2005 Mar; 25(3):379-86. PubMed ID: 15843285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective financial analysis of wellness center from an independent community pharmacy perspective.
    Kent K; McDonough RP; Dinges B; Doucette WR
    J Am Pharm Assoc (2003); 2006; 46(4):447-52. PubMed ID: 16913387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective financial analysis of medication therapy management services from the pharmacy's perspective.
    McDonough RP; Harthan AA; McLeese KE; Doucette WR
    J Am Pharm Assoc (2003); 2010; 50(1):62-6. PubMed ID: 20097640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organization and results of student pharmacist bone mineral density screenings in women.
    Harris AC; Doucette WR; Reist JC; Nelson KE
    J Am Pharm Assoc (2003); 2011; 51(1):100-4. PubMed ID: 21247833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and feasibility of a community pharmacy bone mineral density screening and education program.
    Cerulli J; Zeolla MM
    J Am Pharm Assoc (2003); 2004; 44(2):161-7. PubMed ID: 15098850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis.
    Goode JV; Swiger K; Bluml BM
    J Am Pharm Assoc (2003); 2004; 44(2):152-60. PubMed ID: 15098849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis.
    Naunton M; Peterson GM; Jones G
    Ann Pharmacother; 2006 Jan; 40(1):38-44. PubMed ID: 16303984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist home visits: A 1-year experience from a community pharmacy.
    Monte SV; Passafiume SN; Kufel WD; Comerford P; Trzewieczynski DP; Andrus K; Brody PM
    J Am Pharm Assoc (2003); 2016 Jan; 56(1):67-72. PubMed ID: 26802924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year financial analysis of pharmacy services at an independent community pharmacy.
    Doucette WR; McDonough RP; Mormann MM; Vaschevici R; Urmie JM; Patterson BJ
    J Am Pharm Assoc (2003); 2012; 52(2):181-7. PubMed ID: 22370381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacist-led community bone mineral density screenings.
    Summers KM; Brock TP
    Ann Pharmacother; 2005 Feb; 39(2):243-8. PubMed ID: 15613465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program.
    Carter BL; Chrischilles EA; Scholz D; Hayase N; Bell N
    J Am Pharm Assoc (Wash); 2003; 43(1):24-33. PubMed ID: 12585748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective financial analysis of a herpes zoster vaccination program from an independent community pharmacy perspective.
    Wood HM; McDonough RP; Doucette WR
    J Am Pharm Assoc (2003); 2009; 49(1):12-7. PubMed ID: 19196591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects.
    Mangum SA; Kraenow KR; Narducci WA
    J Am Pharm Assoc (Wash); 2003; 43(1):50-5. PubMed ID: 12585751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postdischarge community pharmacist-provided home services for patients after hospitalization for heart failure.
    Kalista T; Lemay V; Cohen L
    J Am Pharm Assoc (2003); 2015; 55(4):438-42. PubMed ID: 26161487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forging a novel provider and payer partnership in Wisconsin to compensate pharmacists for quality-driven pharmacy and medication therapy management services.
    Trapskin K; Johnson C; Cory P; Sorum S; Decker C
    J Am Pharm Assoc (2003); 2009; 49(5):642-51. PubMed ID: 19748873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility study of community pharmacists performing depression screening services.
    O'Reilly CL; Wong E; Chen TF
    Res Social Adm Pharm; 2015; 11(3):364-81. PubMed ID: 25438728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a community pharmacist-directed clinic in improving screening and awareness of osteoporosis.
    Law AV; Shapiro K
    J Eval Clin Pract; 2005 Jun; 11(3):247-55. PubMed ID: 15869555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoption of a biometric screening service in community pharmacies: a qualitative study.
    Teeter BS; Braxton-Lloyd K; Armenakis AA; Fox BI; Westrick SC
    J Am Pharm Assoc (2003); 2014; 54(3):258-66. PubMed ID: 24816352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.